, 420 men underwent screening for rectal STIs, including 66 (15.7%) who had prevalent rectal infection with CT. An additional 68 participants developed incident infections during 208 person-years of follow-up. Of 134 eligible rectal swab specimens, 128 underwent further testing for LGV serovars. Seven (5.5%) of the tested samples were identified as LGV serovars of CT. None of the seven participants with LGV reported any symptoms such as fever or rectal pain. Two of the participants with LGV were simultaneously co-infected with rectal gonorrhea. HIV co-infection was common among participants with both LGV and non-LGV serovars of CT (71% and 77%, respectively, P = 0.74).
Background. A wild-type gyrase A (gyrA) genotype of N. gonorrheae reliably predicts susceptibility to ciprofloxacin, which can reduce selection pressure for ceftriaxone-resistant infections, an urgent public health threat. In November 2015, UCLA Health began gyrA genotyping all N. gonorrheae positive specimens. In May 2016, we began sending reminder notifications of treatment recommendations to providers of patients with wild-type infections.
Methods. We reviewed records for all laboratory confirmed N. gonorrheae cases from November 1, 2015-April 30, 2017. Infections in different anatomic sites were considered unique infections, while unique infections in a single patient on the same date were considered a case. Empiric therapy was defined as treatment within 1 day of specimen collection. We also collected test-of-cure data among patients with wild-type infections treated with ciprofloxacin.
Results. Among 423 patients (23% HIV infected) there were 460 cases and 514 anatomic site-specific N. gonorrheae infections. Of infections, 218 (43%) had a wildtype gyrA genotype, 138 (27%) mutant, 153 (30%) indeterminate, 4 were not attempted, and 1 had missing data. There were 255 (55%) cases and 283 (55%) infections treated non-empirically. The median time-to-treatment among those cases was 4 days (interquartile range 3-6 days). Ciprofloxacin was used in 2 (3%) of 66 nonempirically treated infections prior to the start of reminder notifications, compared with 40 (18%) of 217 nonempirically treated infections after notifications began (P = 0.002). Of the 55 providers who received an email on or before the day of treatment for non-empirically treated patients, 32 (58%) used ciprofloxacin. There was no ciprofloxacin use prior to assay implementation. The trend in treatment by quarter among non-empirically treated infections is shown the Figure. Among 30 patients treated with ciprofloxacin, 6 had a test of cure at one week, and all (100%; 95% CI 61%-100%) of those tests were negative for N. gonorrheae; 5 were from urethral specimens, and 1 was from the pharynx.
Conclusion. Electronic provider notifications augmented targeted ciprofloxacin therapy for N. gonorrheae infections. Preliminary test-of-cure data are promising.
